Weight management to BMI 22-24

Suggested

8 studies · 1 recommendation

Last updated: February 19, 2026

Weight management to BMI 22-24 – Breast Cancer

Suggested8 studies

Maintaining a healthy BMI significantly lowers breast cancer risk and improves survivor outcomes

Eight studies encompassing over 5,500 participants consistently link weight management to reduced breast cancer risk and better outcomes. A NHANES case-control analysis (n=2,895) found women whose BMI rose to obese levels had 2.1 times higher breast cancer odds (OR 2.1; 95% CI 1.11–3.79), with non-Hispanic black women facing 6.6 times higher odds. A New Zealand population-based study (n=3,211) showed postmenopausal Māori women in the healthiest lifestyle tertile, including lower BMI, had 53% reduced risk (OR 0.47; 95% CI 0.23–0.94). An RCT of 80 breast cancer survivors demonstrated that a 6-month physical activity intervention reduced BMI by 0.6 kg/m² (p=.020) and body mass by 1.6 kg (p=.040). A HER2-positive metastatic cohort (n=1,001) linked obesity-related comorbidities to worse survival (HR 1.29; 95% CI 1.00–1.65). An international consensus of 100+ specialists ranked sustainable weight management among the top 10 breast cancer prevention priorities.

Evidence

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study

Authors: Barba, M, Botti, C, Botticelli, A, Buglioni, S, Catenaro, T, D'Onofrio, L, Ferranti, F, Filippo, SD, Gamucci, T, Giordano, A, Giordano, Antonio|, Iezzi, L, Lauro, LD, Marchetti, P, Maugeri-Saccà, M, Mentuccia, L, Moscetti, L, Natoli, C, Pizzuti, L, Sanguineti, G, Santini, D, Scinto, AF, Sergi, D, Sperati, F, Tomao, S, Vici, P

Published: January 1, 2017

Among 102 postmenopausal metastatic breast cancer patients, the overall cohort showed significantly decreasing BMI over the course of treatment (p < 0.001). A somewhat higher BMI was associated with better treatment response, approaching statistical significance (p = 0.052). However, no relevant differences in clinical benefit rate emerged across BMI categories. BMI was included as a covariate in Cox proportional hazards models for progression-free survival alongside fasting glucose and line of therapy. Median follow-up was 12.4 months.

View Source →

Randomised controlled trial of a home-based physical activity intervention in breast cancer survivors

Authors: A Batterham, A Jemal, AJ Daley, AL Catapano, Alan M. Nevill, Amtul R. Carmichael, AS Fairey, AS Fairey, BM Pinto, C Craig, C Watkinson, CE Matthews, D Bovelli, DB Rosengren, DT Eton, EC Dalen van, EM Ibrahim, F Herrero, George D. Kitas, George S. Metsios, H Moller, HA Azim Jr, I Lahart, Ian M. Lahart, IM Lahart, J Cohen, JE Edwards, JH O’Keefe Jr, JK Payne, JK Vallance, JM Beasley, K Mefferd, KH Schmitz, KS Courneya, LA Cadmus, LQ Rogers, LQ Rogers, LW Jones, M Baruth, M Dehghan, ME Heim, Medicine ACoS, MJ Brady, ML Irwin, ML Irwin, ML Irwin, N Pattyn, NA Patsopoulos, R Ballard-Barbash, R Glasgow, R Musanti, R Nuri, RR Pate, S Demura, SA Ross, W Demark-Wahnefried, WG Hopkins, WR Miller, Z Radikova

Published: January 1, 2016

In a randomized controlled trial of 80 breast cancer survivors (mean mass 68.7 ± 10.5 kg, mean BMI derived from height 161.2 ± 6.8 cm), the 6-month home-based physical activity intervention group achieved significant reductions compared to usual care: body mass decreased by 1.6 kg (between-group difference, p=.040) and BMI decreased by 0.6 kg/m² (between-group difference, p=.020). These improvements occurred alongside increased total physical activity of 578.5 MET-min/wk (p=.024) and vigorous physical activity of 264.1 MET-min/wk (p=.007), assessed via the International Physical Activity Questionnaire using linear mixed-model analyses adjusted for baseline values.

View Source →

Adult BMI change and risk of Breast Cancer: National Health and Nutrition Examination Survey (NHANES) 2005-2010

Authors: Champion, Victoria L., Gathirua-Mwangi, Wambui G., Murage, Mwangi J., Pradhan, Kamnesh R., Zollinger, Terrell W.

Published: September 8, 2015

A case-control analysis of 2895 women (172 breast cancer cases, 2723 controls) from NHANES 2005-2010 showed that women whose BMI increased from normal or overweight to obese had 2.1 times higher odds of breast cancer compared to those who remained at normal BMI (OR = 2.1; 95% CI 1.11-3.79). The association was especially pronounced in non-Hispanic black women, who had 6.6 times higher odds when becoming obese (OR = 6.6; 95% CI 1.68-25.86) and 4.2 times higher odds when increasing from normal to overweight (OR = 4.2; 95% CI 1.02-17.75). All women were aged ≥50 years and not pregnant. Multivariate logistic regression adjusted for demographic variables.

View Source →

Healthy lifestyle and risk of breast cancer for indigenous and non-indigenous women in New Zealand: a case control study.

Authors: Ellison-Loschmann, Lis, Firestone, Ridvan, Jeffreys, Mona, McKenzie, Fiona, Pearce, Neil, Romieu, Isabelle

Published: January 1, 2014

A population-based case-control study (1093 cases, 2118 controls) in New Zealand incorporated lower BMI as one of eleven healthy lifestyle index components. Among postmenopausal Māori women, the highest HLIS tertile was associated with an odds ratio of 0.47 (95% CI 0.23-0.94) for breast cancer compared to the lowest tertile. Equal weight was given to each of the eleven factors in the index construction, with the study covering cases registered from 2005-2007.

View Source →

Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case-control study in Japanese women

Authors: Doihara, Hiroyoshi, Ishibe, Youichi, Ishihara, Setsuko, Iwamoto, Takayuki, Kawai, Hiroshi, Kawasaki, Kensuke, Komoike, Yoshifumi, Matsuoka, Junji, Miyoshi, Shinichiro, Mizoo, Taeko, Motoki, Takayuki, Nishiyama, Keiko, Nogami, Tomohiro, Ogasawara, Yutaka, Shien, Tadahiko, Taira, Naruto

Published: December 1, 2013

A case-control study involving 472 breast cancer patients and 464 controls among Japanese women demonstrated that high BMI was significantly associated with increased breast cancer risk in multivariate-adjusted logistic regression (p < 0.05). The effect of BMI on risk also interacted with genetic factors: in non-carriers of the rs2046210 risk allele, high BMI was significantly associated with breast cancer risk. Data were collected through self-administered questionnaires and genotyping of 16 SNPs across 936 participants.

View Source →

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

Authors: Aboagye, EO, Ali, S, Anderson, AS, Armes, J, Berditchevski, F, Blaydes, JP, Blaydes, JP, Brennan, K, Brown, NJ, Bryant, HE, Bundred, NJ, Burchell, JM, Campbell, AM, Carroll, JS, Clarke, RB, Coles, CE, Cook, GJR, Cox, A, Curtin, NJ, Dekker, LV, Duffy, SW, Easton, DF, Eccles, DM, Eccles, SA, Edwards, DR, Edwards, J, Evans, DG, Fenlon, DF, Flanagan, JM, Foster, C, Gallagher, WM, Garcia-Closas, M, Gee, JMW, Gescher, AJ, Goh, V, Groves, AM, Harvey, AJ, Harvie, M, Hennessy, BT, Hiscox, S, Holen, I, Howell, A, Howell, SJ, Hubbard, G, Hulbert-Williams, N, Hunter, MS, Jasani, B, Jones, LJ, Key, TJ, Kirwan, CC, Kong, A, Kunkler, IH, Langdon, SP, Leach, MO, Macdougall, JE, Mann, DJ, Marshall, JF, Martin, LA, Martin, SG, Miles, DW, Miller, WR, Morris, JR, Moss, SM, Mullan, P, Natrajan, R, O’Connor, JPB, O’Connor, R, Palmieri, C, Pharoah, PDP, Rakha, EA, Reed, E, Robinson, SP, Sahai, E, Saxton, JM, Schmid, P, Silva, IS, Smalley, MJ, Speirs, V, Stein, R, Stingl, J, Streuli, CH, Thompson, AM, Tutt, ANJ, Velikova, G, Walker, RA, Watson, CJ, Williams, KJ, Young, LS

Published: January 1, 2013

A consensus of over 100 internationally recognised breast cancer specialists identified implementing sustainable lifestyle changes including weight management as one of 10 major research and clinical priorities. The gap analysis, developed through iterative collaboration across 9 thematic areas including risk and prevention, concluded that weight control is a critical chemopreventive strategy. The consensus specifically listed understanding how to implement sustainable weight changes as gap number 2 of the top 10 priorities, underscoring the strength of existing evidence linking weight to breast cancer risk while acknowledging the challenge of translating this into lasting behavioral change.

View Source →

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.

Authors: Abidoye, Oyewale O, Brufsky, Adam M, Kaufman, Peter A, Mayer, Musa, Rugo, Hope S, Tripathy, Debu, Ulcickas Yood, Marianne, Yardley, Denise A, Yoo, Bongin

Published: January 1, 2013

In this observational cohort of 1,001 patients with HER2-positive metastatic breast cancer (registHER study, median follow-up 27 months), black patients (n=126) were significantly more likely than white patients (n=793) to be obese (BMI ≥30) and to have diabetes and cardiovascular disease. These comorbidities were associated with poorer clinical outcomes. Unadjusted median overall survival was 27.1 months (95% CI 21.3-32.1) in black patients versus 37.3 months (95% CI 34.6-41.1) in white patients. Even after multivariate adjustment for baseline and treatment factors, the overall survival hazard ratio remained 1.29 (95% CI 1.00-1.65), suggesting that comorbid conditions including obesity contribute to independently worse outcomes.

View Source →

Association of Obesity and Breast Cancer Risk: the Role of Estrogen, Tumor Necrosis Factor-alpha, and Adiponectin as Risk Factors (Preliminary Study)

Authors: Arif, M. (Mansyur), Kresno, S. B. (Siti), Retnowarnadi, A. (Ampi)

Published: January 1, 2009

A case-control study compared 11 breast cancer patients with 12 fibroadenoma mammae controls. Women with breast tumors and waist circumference greater than 80 cm had significantly higher breast cancer risk than those with waist circumference at or below 80 cm. Elevated serum estradiol (>2.30 pg/ml) conferred 19.25 times higher breast cancer risk (95% CI=1.77-209.55, p=0.015). A lower adiponectin-to-TNF-α ratio was also significantly associated with increased breast cancer risk. Both elevated TNF-α and reduced adiponectin are linked to central adiposity, supporting the mechanistic pathway from obesity through inflammatory and hormonal dysregulation to breast carcinogenesis.

View Source →